Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce R Schackman

Showing results (141-150 of 222) with videos related to

Pageof 23
Sort By:
Journal of Substance Abuse Treatment|September 22, 2019
Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York CityCzarina N Behrends, Denise Paone, Michelle L Nolan, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 24, 2024
Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A Systematic ReviewCzarina N Behrends, Jared A Leff, Weston Lowry, et al.
Drug and Alcohol Dependence|February 6, 2022
Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020Czarina N Behrends, Xinlin Lu, Grace J Corry, et al.
Medical Care|October 26, 2006
The lifetime cost of current human immunodeficiency virus care in the United StatesBruce R Schackman, Kelly A Gebo, Rochelle P Walensky, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2019
Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment ProgramsSarah Gutkind, Bruce R Schackman, Jake R Morgan, et al.
JAMA Health Forum|May 19, 2023
Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use OpioidsAnneke L Claypool, Catherine DiGennaro, W Alton Russell, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluationBruce R Schackman, Jared A Leff, Michael Botsko, et al.
Addiction (Abingdon, England)|May 5, 2021
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysisSean M Murphy, Philip J Jeng, Kathryn E McCollister, et al.
The International Journal on Drug Policy|September 5, 2021
Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode IslandXiao Zang, Alexandria Macmadu, Maxwell S Krieger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 30, 2006
Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patientsKenneth A Freedberg, Lisa R Hirschhorn, Bruce R Schackman, et al.
Pageof 23

Showing results (141-150 of 222) with videos related to

Sort By:
Pageof 23
Journal of Substance Abuse Treatment|September 22, 2019
Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York CityCzarina N Behrends, Denise Paone, Michelle L Nolan, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 24, 2024
Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A Systematic ReviewCzarina N Behrends, Jared A Leff, Weston Lowry, et al.
Drug and Alcohol Dependence|February 6, 2022
Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020Czarina N Behrends, Xinlin Lu, Grace J Corry, et al.
Medical Care|October 26, 2006
The lifetime cost of current human immunodeficiency virus care in the United StatesBruce R Schackman, Kelly A Gebo, Rochelle P Walensky, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2019
Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment ProgramsSarah Gutkind, Bruce R Schackman, Jake R Morgan, et al.
JAMA Health Forum|May 19, 2023
Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use OpioidsAnneke L Claypool, Catherine DiGennaro, W Alton Russell, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluationBruce R Schackman, Jared A Leff, Michael Botsko, et al.
Addiction (Abingdon, England)|May 5, 2021
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysisSean M Murphy, Philip J Jeng, Kathryn E McCollister, et al.
The International Journal on Drug Policy|September 5, 2021
Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode IslandXiao Zang, Alexandria Macmadu, Maxwell S Krieger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 30, 2006
Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patientsKenneth A Freedberg, Lisa R Hirschhorn, Bruce R Schackman, et al.
Pageof 23